经皮睾酮与雌激素治疗对绝经后女性干眼的影响:一项随机、安慰剂对照、先导研究
这项随机双盲安慰剂对照先导研究纳入40例绝经后干眼女性,分为经皮睾酮组、雌二醇组、睾酮/雌二醇联合组和安慰剂组各10例,评估8周后症状与体征变化。结果显示雌激素组干眼强度较安慰剂组显著加重(p=0.04),其他症状及泪液功能等指标组间无显著变化;睾酮对症状无明显影响。作者认为雌激素补充可能加重绝经后干眼患者的眼部症状,而睾酮对症状无明显影响,激素对泪液功能的正面效应需在更大样本研究中确认。
要点
- 雌激素组8周后干眼强度较安慰剂组显著加重(p=0.04)。
- 其他症状、泪液功能、睑板腺功能、眼睑形态及角结膜敏感度各组与安慰剂相比无显著变化。
- 睾酮/雌二醇联合组组内泪液分泌增加(p=0.03),睾酮组血清雄激素升高与泪膜稳定性改善强相关(ρ=0.83,p=0.01)。
核心结论
- 雌激素补充可能加重绝经后干眼女性的眼部症状,而睾酮治疗对症状无明显影响。
- 雌激素和睾酮对泪液功能的正面效应需在更大样本研究中确认,样本量应基于本研究数据计算。
- 安慰剂对照在干眼治疗研究中至关重要。
研究设计与样本
- 随机双盲安慰剂对照先导研究,纳入40例绝经后干眼女性(年龄63.9±5.1岁,绝经13.2±6.3年)。
- 受试者分为四组各10例:经皮睾酮组、雌二醇组、睾酮/雌二醇联合组和安慰剂组。
- 基线和8周后评估眼部症状、泪液渗透压、泪膜稳定性、泪液分泌、睑板腺评估、角结膜敏感度及血清17β-雌二醇、3-α-雄烷二醇葡萄糖苷酸和硫酸脱氢表雄酮浓度。
- 组间差异采用单因素方差分析和Dunnett t检验,组内分析采用配对t检验和Spearman相关。
主要发现
- 8周后雌激素组干眼强度较安慰剂组显著更差(p=0.04)。
- 其他症状、泪液功能、睑板腺功能、眼睑形态、角结膜敏感度各组与安慰剂组8周变化相比均无显著变化。
- 睾酮/雌二醇联合组组内泪液分泌增加(p=0.03)。
- 睾酮组血清雄激素升高与泪膜稳定性改善强相关(ρ=0.83,p=0.01)。
关键数值与推荐
- 8周后雌激素组干眼强度较安慰剂组显著更差(p=0.04)。
- 睾酮/雌二醇联合组组内泪液分泌增加(p=0.03)。
- 睾酮组血清雄激素升高与泪膜稳定性改善强相关(ρ=0.83,p=0.01)。
临床怎么用
- 作者认为雌激素补充可能加重绝经后干眼女性的眼部症状,而睾酮治疗对症状无明显影响。
- 作者指出雌激素和睾酮对泪液功能的正面效应需在更大样本研究中确认,样本量应基于本研究数据计算。
- 作者强调安慰剂对照在干眼治疗研究中至关重要。
局限性
- 本文为先导研究,样本量小(40例,每组10例)。
- 作者指出雌激素和睾酮对泪液功能的正面效应需在更大样本研究中确认,样本量应基于本研究数据计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Sex hormones could provide a future treatment avenue for dry eye post menopause. However, there are few well-controlled studies. This study investigates the impact of testosterone and oestrogen on dry eye symptoms and signs in postmenopausal women. METHODS: A randomised double-blind placebo-controlled pilot study was conducted involving 40 women with dry eye (age 63.9±5.1 years, 13.2±6.3 years post menopause). Ten women were assigned to each of four treatment groups: transdermal testosterone, oestradiol, testosterone/oestradiol combination and placebo. Assessment at baseline and after 8 weeks: ocular symptoms, tear osmolarity, tear stability, tear secretion, meibomian gland assessment, corneal and conjunctival sensitivity, serum concentrations of 17β-oestradiol, 3-α-androstanediol-glucuronide and dehydroepiandrosterone sulfate. Differences from placebo were examined using one-way analysis of variance and Dunnett's t-test. Within-group analyses included paired t-tests and Spearman correlation. RESULTS: Dryness intensity after 8 weeks was significantly worse in the oestrogen group compared with placebo (p=0.04). No significant changes in other symptoms, tear function, meibomian gland function, lid morphology, corneal or conjunctival sensitivity were observed in any of the groups when compared with the change in placebo after 8 weeks. Within-group analyses showed increased tear secretion in the testosterone/oestradiol combination group (p=0.03) and a strong association between increased serum androgen and improved tear stability in the testosterone group (ρ=0.83,p=0.01). CONCLUSIONS: Oestrogen supplementation may worsen ocular symptoms in postmenopausal women with dry eye, whereas no impact of testosterone therapy on symptoms was apparent. The positive effects of oestrogen and testosterone on tear function require confirmation in a larger study, with sample size calculated from the data generated herein. Placebo control is essential in studies of dry eye therapies. TRIAL REGISTRATION NUMBER: ACTRN12612000281897.
引用
- Golebiowski B, Badarudin N, Eden J, et al. The effects of transdermal testosterone and oestrogen therapy on dry eye in postmenopausal women: a randomised, placebo-controlled, pilot study. Br J Ophthalmol. 2016. PMID: 27811278. doi:10.1136/bjophthalmol-2016-309498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。